|
GSK and Theravance announce combination ICS/LABA Phase II results in the …
MarketWatch (press release) Our ongoing collaboration with GSK includes the Phase III programmes in both COPD and asthma, which are already underway for Relovair and its components. … Theravance Announces Results From Phase II Study For Developmental Combination … |
View full post on asthma – Google News